Leslie Bottorff joined ONSET Ventures in 1998 after 19 years in the medical industry. At ONSET Ventures, Leslie specializes in medical technology investment opportunities. She has worked closely with several portfolio company entrepreneurs at the seed stage to formulate and validate their companies' business plans, including Curon Medical, Novasys Medical and Embolic Protection, where she was interim VP of Marketing and Business Development at inception. Leslie has served in board or advisory roles for several portfolio companies including Spinal Concepts, Novasys Medical, VisionCare Ophthalmic Technologies, Neuronetics, Sadra Medical and CardioMind.

Prior to joining ONSET, Leslie was VP of Sales and Marketing of Medtronic’s CardioRhythm division. She has also served in various marketing and sales management positions at both venture backed start-up companies and in large companies, including Nellcor, Ventritex, Menlo Care and General Electric's Medical Systems division.

Leslie has a B.S. in Biomedical Engineering from Purdue University and an MBA from Harvard Business School. She serves on advisory boards or as program faculty at several universities, including Stanford University and Purdue University.

Brook Byers has been a venture capital investor since 1972. He has been closely involved with more than forty new technology based ventures, over half of which have already become public companies. He formed the first Life Sciences practice group in the venture capital profession in 1984 and led KPCB to become a premier venture capital firm in the medical, healthcare, and biotechnology sectors. KPCB has invested in and helped build over 90 Life Sciences companies which are developing hundreds of products to treat major underserved medical needs representing huge markets in the nearly two trillion dollar healthcare sector.

Since 1979, David has been actively involved in managing and investing in over 50 high growth venture capital backed companies, primarily in the medical device industry. He joined Delphi Ventures in 1990. Prior to joining Delphi, David was a General Partner at Matrix Partners focusing on medical device investments.

From 1984 to 1986, David served as Chief Operating Officer at Paladin Software Corporation, responsible for operations, R&D, finance and administration. From 1979 to 1983, David served as Vice President of Finance and Administration at Collagen Corporation. He was responsible for several private equity financings, as well as Collagen's initial public offering. Before joining Collagen, David was a consultant with McKinsey & Company.

David has served as a Director of the Western Association of Venture Capital and presently serves as a director of the Stanford University Athletic Board and as a member of the Stanford University School of Education Advisory Board. Additionally, in 2005, David was named to Forbes Midas List identifying the top 100 dealmakers in the venture capital industry.

During the past four years, Nina Fernandes has been engaged as a consultant for Bay Area medical device / healthcare firms, including De Novo Ventures, Guidant Corporation, VNUS Medical, and Conor Medsystems. Prior to that, Nina served in various sales and marketing management roles with Guidant Corporation and the Clorox Company. She holds an MBA from Indiana University and a BS from Boston College.

Following De Novo’s investment in Cryovascular Systems in 2000, Rich joined the initial five-person team as the start-up CEO. He built the company to 22 employees, was instrumental in developing the clinical and product strategies, and hired the executive team. In 2002, Rich led Paracor Medical, another De Novo portfolio company. He grew Paracor from its initial 4 to 22 employees, refined the product strategy, raised its Series B round, and hired his replacement CEO.

In 1996 he founded Saratoga Ventures, a venture capital partnership that has provided seed financing to several successful companies, including Atrionix, Oratec, Enteric Medical, Trivascular, and Endotex. Oratec, a portfolio company of which Rich was Chairman, went public and was ultimately acquired by Smith & Nephew.

Rich was also the co-founder of Integrated Vascular Systems (which was recently purchased by Abbott) an early stage femoral artery closure company and Angiosense, a needle-free, jet injection, local drug delivery company. Early in his career, Rich held the position of Executive Vice President and General Manager of ADAC Laboratories.

Rich is the recipient of the Mallinckrodt Award for Excellence in Medicine and twice a finalist for the Entrepreneur of the Year Award.

Dr. McColl previously served as President, Director, and Executive Committee Member of the Stanford DAPER Investment Fund (beginning in 1997), and as Managing Director of Chelsea Investments, LLC, (beginning in 1998), and maintains active involvement in both. He was also a Professional Athlete with the San Francisco Forty Niners (1981 – 1987) and with the Los Angeles Raiders (1988), and is a two-time Super Bowl and World Champion.

Dr. McColl received his M.D. from the Stanford University School of Medicine in 1987, and his BS in Biology from Stanford University in 1981.

She is a founding member of the Stanford Entrepreneurship Network, whose mission is to support entrepreneurship education, research and collaboration campus-wide. Sandra has produced physician education video series on revolutionary interventional cardiology innovations such as intravascular ultrasound (IVUS – Paul G. Yock, MD, inventor) and directional coronary atherectomy (DCA – John B. Simpson, PhD, MD, inventor). She holds an MBA degree from Pepperdine University.

With nearly twenty years of experience in biomedical research and corporate management, Dr. Timothy Mills joined Sanderling as an Operating Partner in July 1998, and was promoted to Managing Director in 2000. At Sanderling, Dr. Mills has focused on early stage investments in Medical Devices, Biotherapeutics, and i-Health. He serves Sanderling portfolio companies as Director, Chief Executive Officer or management team member.

Prior to joining Sanderling, Dr. Mills served as the Corporate Vice President of New Business Development and Chief Scientific Officer of Target Therapeutics, a medical device company that was acquired by Boston Scientific in 1997.

Prior to joining Target in 1994, Dr. Mills served as Director of Business Development and Advanced Research & Development in the Interventional Cardiology Division of Baxter Healthcare. Dr. Mills' academic appointments include service as the Director of the Artificial Heart Program at the University of California, Irvine Medical Center and membership in the University of California, San Francisco Radiology Department.

Dr. Mills received his Ph.D. in Bioengineering from the University of California, Berkeley & San Francisco School of Medicine, his M.S. in Electrical Engineering & Computer Science from the University of California, Berkeley, and his B.S. in Electrical Engineering from the University of Colorado, Boulder.

Mr. Nash co-founded iScience Surgical, a medical device company developing microcatheters and imaging systems for the surgical treatment of sight-threatening eye diseases. He currently serves as President and CEO of iScience Surgical. Prior to iScience Surgical, Mr. Nash held a wide range of senior management positions at Oculex Pharmaceuticals Inc. (Allergan), Ioptex Research Inc. (Advanced Medical Optics), General Surgical Innovations Inc. (Tyco), and Orthopedic Technology Inc. (J&J). Throughout his career, Mr. Nash has been recognized for his ability to identify and execute product opportunities from concept to commercialization. Mr. Nash has an extensive background in market research, market development, and business development. Mr. Nash graduated from the University of Michigan with degrees in economics and journalism.

Erica is the President and CEO of Allux Medical, a company formed out of a medical device incubator backed by Three Arch partners, Prospect Ventures, and Venrock. Allux is developing novel technology for the treatment of hyper-reactive airway. Erica is also the co-founder of Visiogen, an ophthalmic company developing a dual optic accommodating lens. She is the co-inventor of the lens and holds over eight issued or pending patents in the medical device and nanotechnology areas. Erica spent over 12 years at Boston Scientific, working up through sales and marketing of Medi-tech and Target. She has extensive experience in cardiovascular, peripheral vascular, and neurovascular interventional medicine. After a degree in zoology, she began her career at the Upjohn Company.

Additionally, Weinstein was an Associate at A.T. Kearney, a global strategy-consulting firm. He also worked with a venture capital funded developer of machine control software and, for eight years, served as General Partner of a small regional firm, where he managed commercial real estate.

Prior to joining Prism in 2001, Weinstein was a Principal and Kauffman Fellow with Mid-Atlantic Venture Funds. There he invested in and served as a board observer for several early-stage communications and software companies.

Weinstein has an M.B.A. with distinction from the University of Michigan Business School and a B.S. in mechanical engineering from Columbia University’s School of Engineering and Applied Science.

Weinstein’s focus is medical devices. He is currently on the board of or a board observer to the following companies: iScience Surgical, Rox Medical, Coaxia Inc., and Sensitech Inc.

Dr. Yock is known for his work in inventing, developing and testing new devices, including the Rapid Exchange ™ balloon angioplasty system, which is now the primary system in use worldwide. He also invented a Doppler-guided access system known as the Smart Needle™ and PD-Access™. The main focus of Dr. Yock’s research program has been in the field of intravascular ultrasound. He authored the fundamental patents for intravascular ultrasound imaging and conducted the initial clinical trials. In 1986 he founded Cardiovascular Imaging Systems, which was acquired by Boston Scientific in 1994. Dr. Yock has authored over 40 US patents, 300 peer-reviewed publications, chapters and editorials, and a textbook.

Current research interests of Dr. Yock’s group include development and testing of catheter-based delivery systems for cardiac cell transplantation and new catheter and molecular imaging techniques for cardiology.

Dr. Yock also directs the Program in Biodesign, a unit of Stanford’s new Bio-X initiative that focuses on invention and technology transfer related to biomedical engineering.